series-a
Stage
1
Investors
About
Catena Bio develops a proprietary conjugation platform enabling the creation of multi-payload antibody-drug conjugates with enhanced stability and therapeutic potential, primarily targeting solid tumors with high unmet needs.
Explore Catena Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.